Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio

 Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio

Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio

Shots:

  • Pfizer acquires Therachon, in all stock transaction for $810M. Therachon to receive $340M upfront with additional payment on milestones of development and commercialization of its  TA-46 candidate targeted for achondroplasia
  • Additionally, Therachon to spin-off its apraglutide development program into an independent firm, prior closure of the transaction. Pfizer Ventures to hold an equity stake in the new firm
  • TA-46 is a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy has completed its P-I for achondroplasia and has received EMA’s and FDA’s ODD. Apraglutide is a qw GLP-2 analog P-II candidate targeted for short bowel syndrome

Click here to read full press release/ article | Ref: Pfizer | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post